GLPG (Galapagos) Future Price to Earnings

Official company branding of Galapagos (GLPG)

Global conflicts are hindering international drug trials and disrupting component logistics. The future P/E multiple for Galapagos NV on GURU.Markets reflects a search for market equilibrium, with the parameter reaching 0.00. The prospects for Galapagos NV rely on CAR-T therapy and the alliance with Gilead, while a massive cash reserve completely offsets R&D costs and financial risks.

glpg.com - GLPG Market Cap to Future Earnings Ratio (period 07/04/2022 - 05/08/2026)

Summary analytical data breakdowns for glpg.com (GLPG)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Galapagos N.V.
Brand item of Galapagos NV

Professional capital evaluates Galapagos NV through the lens of future profitability, where the risks of global clinical trial disruptions due to geopolitics directly impact earnings forecasts. The current change in the company's expected P/E ratio at 0.00 reflects the market consensus on the share price relative to upcoming net income, allowing investors to determine the extent of the asset's premium amid logistical instability.

Competitor analysis

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio anipharmaceuticals.com ANIP|Future Price to Earnings MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP